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Abstract
Background: We evaluated the associations between single nucleotide polymorphisms and different clinical parameters
related to type 2 diabetes mellitus (T2DM), obesity risk, and metabolic syndrome (MS) in a Kazakh cohort.
Methods: A total of 1336 subjects, including 408 T2DM patients and 928 control subjects, were recruited from an
outpatient clinic and genotyped for 32 polymorphisms previously associated with T2DM and obesity-related
phenotypes in other ethnic groups. For association studies, the chi-squared test or Fisher’s exact test for
binomial variables were used. Logistic regression was conducted to explore associations between the studied
SNPs and the risk of developing T2DM, obesity, and MS, after adjustments for age and sex.
Results: After excluding four SNPs due to Hardy-Weinberg disequilibrium, significant associations in age-matched
cohorts were found betweenT2DM and the following SNPs: rs9939609 (FTO), rs13266634 (SLC30A8), rs7961581
(TSPAN8/LGR5), and rs1799883 (FABP2). In addition, examination of general unmatched T2DM and control cohorts
revealed significant associations between T2DM and SNPsrs1799883 (FABP2) and rs9939609 (FTO). Furthermore,
polymorphisms in the FTO gene were associated with increased obesity risk, whereas polymorphisms in the FTO
and FABP2 genes were also associated with the risk of developing MS in general unmatched cohorts.
Conclusion: We confirmed associations between polymorphisms within the SLC30A8, TSPAN8/LGR5, FABP2, and
FTO genes and susceptibility to T2DM in a Kazakh cohort, and revealed significant associations with anthropometric
and metabolic traits. In particular, FTO and FABP2 gene polymorphisms were significantly associated with susceptibility
to MS and obesity in this cohort.
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Background
Type 2 diabetes mellitus (T2DM) is the most widespread
endocrine disease and one of the most acute medical
and societal problems, as it leads to early disability and
increased mortality from different complications [1, 2].
More than 170 million people currently suffer from T2DM
[3]. According to the Kazakhstan Diabetes Association, by
the end of 2013, more than 273,000 individuals were iden-
tified as having type 1 or type 2 diabetes; this accounts for
1.6% of the country’s population. Moreover, T2DM is the
predominant form of diabetes in Kazakhstan, as it was de-
tected in 93% of diabetes patients [4].
T2DMis a multifactorial disease; its pathogenesis is
characterised by β-cell dysfunction accompanied by re-
duced insulin secretion and β-cell mass, increased gluca-
gon secretion, a diminished incretin response, augmented
liver glucose production, enhanced glucose reabsorption,
activated lipolysis, reduced glucose absorption by the
muscles, and neurotransmitter dysfunctions [5, 6]. Many
* Correspondence: ksnurgul@gmail.com
1National Center for Biotechnology, 13/5 Korgalzhyn str, Astana 010000,
Kazakhstan
2L.N. Gumilyov Eurasian National University, Astana, Kazakhstan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sikhayeva et al. BMC Medical Genetics  (2017) 18:76 
DOI 10.1186/s12881-017-0443-2
studies have revealed connections between T2DM and
obesity and metabolic syndrome (MS). Genetic variation
and environmental factors are thought to contribute to
the development of T2DM. The greatest progress in the
identification of genetic factors underlying T2DM has
been achieved using genome-wide association studies
(GWAS) in different populations [6]. However, positive
associations need to be evaluated in other ethnic popula-
tions, due to associated differences in the frequencies of
genetic variants, and also because of differences in the
contribution of environmental factors [6–10].
More than 100 genetic variants are currently thought to
be associated with the risk of developing T2DM. The
majority of these genes affect insulin secretion [6, 11, 12],
although the exact molecular mechanisms through which
this occurs remain largely unknown. The present study
aimed to determine whether 32 genetic polymorphisms,
previously identified by GWAS and candidate gene studies
using other ethnic populations, are associated with sus-
ceptibility to T2DMand obesity-related phenotypes in a
Kazakh cohort. Different clinical metabolic phenotypes re-
lated to T2DM, such as body mass index (BMI), blood
pressure, waist to hip circumference, plasma levels of
glucose, cholesterol, triglycerides (TGs), low-density
lipoproteins (LDL), high-density lipoproteins (HDL),
C-peptide, and glycosylated haemoglobin (HbA1c)
were also examined.
Methods
Subjects and clinical tests
Samples were collected from one region of Kazakhstan
(Almaty). The study participants included only ethnic
Kazakhs, according to self-reported information; partici-
pants who self-identified as being of Russian, Western
European, East Asian, or Middle Eastern origin were ex-
cluded. Blood samples were obtained from 408 T2DM
patients recruited from the outpatient clinic of the
Asfendiyarov Kazakh National Medical University (Al-
maty, Kazakhstan). T2DM was diagnosed according to
the World Health Organization (WHO) criteria, specifi-
cally, fasting plasma glucose ≥7.0 mmol/L, and/or
HbA1c test ≥6.5%,and/or postprandial plasma glucose
test ≥11.1 mmol/L, and/or the prescription of antidia-
betic medications [13, 14]. Nine hundred and twenty-
eight control subjects were included after receiving an
annual health check-up conducted at the Asfendiyarov
Kazakh National Medical University. Individuals from
the control group were unrelated, randomly selected,
and had not been diagnosed with T2DM.In the control
group, there were several participants with elevated
levels of glucose and HbA1c. These individuals had not
been diagnosed with diabetes before sampling or during
health check-up, at which time blood samples were
collected from these participants. Therefore, we did
not exclude these samples from the control group.
Participants with acute diseases and women who were
pregnant were also excluded from the control group.
Overweight and obesity were defined according to the
WHO criteria as follow: normal weight, 18.5 kg/m2 ≤ body
mass index (BMI) <25 kg/m2; overweight, 25 kg/
m2 ≤ BMI ≤ 30 kg/m2; obesity, BMI >30 kg/m2. The pre-
sence of at least three of the following components
defined MS (ATPIII criteria): central obesity (waist cir-
cumference (WC) >88 cm in women, >102 cm in men),
hypertriglyceridemia (TGs ≥1.6 mmol/L), HDL choles-
terol <1.3 mmol/L, hypertension (systolic blood pres-
sure (SBP) ≥130 mmHg or diastolic blood pressure
(DBP) ≥85 mmHg), fasting plasma glucose ≥5.5 mmol/L,
or drug treatment for elevated blood glucose [15].
Anthropometric indices including weight, height, WC,
and blood pressure were measured following standard
protocols. Height and weight were measured with the
participants wearing light clothes and without shoes.
WC was measured at the midpoint between the iliac
crest and lowest rib. Hip circumference (HC) was mea-
sured to the nearest centimetre at the greatest protru-
sion of the buttocks, just below the iliac crest. Blood
pressure was measured in a sitting position with a mer-
cury sphygmomanometer. BMI was calculated as the
individual’s body weight in kilograms divided by the
square of his/her height in meters. Waist to hip ratio
was calculated as WC in centimetres divided by the HC
in centimetres. Biochemical variables including fasting
blood glucose, TGs, cholesterol, HDL, LDL, and HbA1c,
were measured using blood samples collected after over-
night fasting with biochemical auto-analysers (BioChem
Analette, HTI, Walpole, MA, USA and Cobas c 111,
Roche Diagnostics Ltd., Rotcreuz, Switzerland). Fasting
insulin and C-peptide (used only for classification of
diabetes and not measured in the control group) were
determined using automated enzyme immunoassays and
a ChemWell 2910 chemistry analyser (Awareness Tech-
nologies, Palm City, FL, USA).
Written informed consent was obtained from all par-
ticipants and the protocol was approved by the Ethics
Committee of National Centre for Biotechnology, Astana,
Kazakhstan (No. 10.14.03.2012).
SNP selection and genotyping
We selected 32 genetic polymorphisms previously asso-
ciated with T2DM and obesity-related phenotypes for
investigation in this study (Table 1). DNA was extracted
using the salting-out method [16]. SNPs were detected
using the TaqManOpenArray Real-Time PCR Platform
(LifeTechnologies, Foster City, CA, USA). Analyses
were conducted according to the manufacturer’s stan-
dard protocols and genotype calls were made by Open-
Array SNP Genotyping Analysis Software, version 1.0.3.
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Data analyses were performed using TaqManGenotyper
Software V1.3.
Statistical analysis
Quantitative data are presented as median and range un-
less otherwise mentioned, whereas qualitative data are
presented as percentages. Statistical analysis was per-
formed using R software (version 3.1.2, Foundation for
Statistical Computing, Vienna, Austria) and Arlequin
software (version 3.1.2, University of Bern, Bern,
Switzerland) [17–19]. The conformance of genotype fre-
quency distributions to the Hardy–Weinberg equilib-
rium (HWE) was assessed using the χ2 criterion
(α = 0.05, df = 2). For association studies, the chi-square
test or Fisher’s exact test for binomial variables was used.
Logistic regression was conducted to determine the as-
sociation between the studied SNPs and the risk of
T2DM, obesity and MS, after adjustments for age and
Table 1 Characteristic of selected SNPs
SNP ID Gene or nearby
region
Location Position Traits OR [95% CI] References
rs3751812 FTO 16q12.2 Intron 1 Obesity 1.42 [1.33–1.52] Frayling et al., 2007 [60]
rs8050136 FTO 16q12.2 Intron 1 T2DM; obesity 1.22 [1.07–1.40] 1.45
[1.09–1.93]
Liu et al., 2010 [26]
rs9939609 FTO 16q12.2 Intron 1 T2DM; obesity 1.19 [1.04–1.37]; 1.39
[1.04–1.85]
Liu et al., 2010 [26]
rs10811661 CDKN2A/B 9p21.3 Intergenic T2DM 1.20 [1.14–1.25] Zeggini et al., 2007 [27]
rs2383208 CDKN2A/B 9p21.3 Intergenic T2DM 1.34 [1.27–1.41] Takeuchi et al., 2009 [28]
rs1111875 HHEX 10q23.33 3′-UTR T2DM 1.21 [1.15–1.28] Takeuchi et al., 2009 [28]
rs5015480 HHEX 10q23.33 Intergenic T2DM 1.17 [1.11–1.24] Zegginietal., 2008
rs13266634 SLC30A8 8q24.11 Exon 8, missense T2DM 1.16 [1.10–1.22] Rung et al., 2009 [29],
Takeuchi et al., 2009 [28]
rs4506565 TCF7L2 10q25.3 Intron 3 T2DM 1.36 [1.20–1.54] Wellcome Trust Case Control
Consortium (2007) [30]
rs7903146 TCF7L2 10q25.3 Intron 4 T2DM 1.49 [1.39–1.59] Timpson et al., 2009 [31]
rs4402960 IGF2BP2 3q27.2 Intron 2 T2DM 1.14 [1.08–1.21] Takeuchi et al., 2009 [28]
rs5215 KCNJ11 11p15.1 Exon 1 T2DM 1.16 [1.09–1.23] Zeggini et al., 2008 [12]
rs7756992 CDKAL1 6p22.3 Intron 5 T2DM 1.20 [1.13–1.27] Steinthorsdottir et al., 2007 [32]
rs4712523 CDKAL1 6p22.3 Intron 5 T2DM 1.27 [1.21–1.33] Takeuchi et al., 2009 [28]
rs9465871 CDKAL1 6p22.3 Intron 5 T2DM 1.18 [1.04–1.34] Wellcome Trust Case Control
Consortium (2007) [30]
rs7961581 nearTSPAN8/LGR5 12q21.1 Intergenic T2DM 1.09 [1.06–1.12] Zeggini et al., 2008 [12]
rs864745 JAZF1 7p15.2-p15.1 Intron 1 T2DM 1.10 [1.07–1.13] Zeggini et al., 2008 [12]
rs12779790 nearCDC123/CAMK1D 10p13 Intergenic T2DM 1.11 [1.07–1.14] Zeggini et al., 2008 [12]
rs10490072 BCL11A 2p16.1 3′ ofgene T2DM 1.05 [1.03–1.08] Zeggini et al., 2008 [12]
rs10923931 NOTCH2 1p13-p11 Intron 5 T2DM 1.13 [1.08–1.17] Zeggini et al., 2008 [12]
rs7578597 THADA 2p21 Exon 24, missense T2DM 1.15 [1.10–1.20] Zeggini et al., 2008 [12]
rs2025804 LEPR 1p31 Intron 2 BMI Traurig et al., 2012 [33]
rs2641348 ADAM30 1p12 Exon 1, missense T2DM 1.10 [1.06–1.15] Zeggini et al., 2008 [12]
rs9472138 near VEGFA 6p21.1 Intergenic T2DM 1.06 [1.04–1.09] Zeggini et al., 2008 [12]
rs1042714 ADRB2 5q31-q32 Exon 1, missense T2DM 0.56 [0.36–0.91] Pinelli et al., 2006 [34]
rs4994 ADRB3 8p12 Exon 1, missense T2DM 1.27 [1.07–1.51] Jing et al., 2012 [35]
rs1799883 FABP2 4q28-q31 Exon 2, missense T2DM 1.29 [1.08–1.49] Qiu et al., 2014 [8]
rs1801282 PPARG 3p25 Exon 4, missense T2DM 1.14 [1.08–1.20] Scott et al., 2007 [11]
rs8192678 PPARGC1A 4p15.1 Exon 8, missense T2DM 1.07 [1.00–1.15] Barroso et al., 2006 [37]
rs780094 GCKR 2p23 Intron 16 T2DM 0.71 [0.58–0.85] Onuma et al., 2010 [38]
rs7944584 MADD 11p11.2 Intron 25 T2DM 1.63 [1.32–2.02] Hu et al., 2010 [39]
rs1153188 DCD-VDAC1P5 12q13 Intergenic T2DM 1.08 [1.05–1.11] Zeggini et al., 2008 [12]
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sex. Odds Ratios (ORs) were calculated and presented
with 95% confidence interval (CI) values. For quantitative
non-parametric data, the Wilcoxon signed rank sum test
was used to compare variables between two groups and
the Kruskal-Wallis test was used when variables were
compared between three groups. Differences were consid-
ered statistically significant if P < 0.05. For genetic ana-
lysis, the additive model was used. Power analysis (with
β = 0.20 and α = 0.05) was performed using Power and
Sample Size Calculation software (version 3.1.2, Vanderbilt
University, Nashville, Tennessee, USA) designed by W.D.
Dupont and W.D. Plummer [20]. Data from the HapMap
database were used for the comparative analysis of dif-
ferences in genotype and haplotype frequencies among
Kazakh and world populations (HapMap Genome
Browser release #27 [Phases 1–3: merged genotypes and
frequencies]) [21]. The exact test of the population diffe-
rentiation (Markov chain) method was used for analysis.
The burn-in period of 10,000 dememorisation steps was-
followed by 100,000 Markov-Chain steps [22].
Results
General T2DM and control cohorts
Baseline clinical characteristics of the 1336 subjects (928
control subjects and 408 individuals withT2DM) are
listed in Table 2. There were 257 males and 671 females
in the control group (median age 32 [range, 18–61]
years, median BMI 23.0 [range, 15.1–54.0] kg/m2,
median fasting plasma glucose 4.9 [range, 3.2–7.8]
mmol/L). The T2DM group consisted of 182 males and
226 females (median age 59 [range, 29–84] years, median
BMI 29.3 [range, 18.2–47.6] kg/m2, median fasting plasma
glucose 9.6 [range, 3.6–30.5] mmol/L). With the exception
of height, all measured parameters significantly differed
between the patients and control subjects.
Age-matched T2DM and control cohorts
T2DM usually develops in middle-aged and older indi-
viduals. Because the control group consisted of subjects
younger than those in T2DM group, to avoid bias (i.e. the
inclusion of young controls with genetic risk factors for
developingT2DM), a subset of control subjects was age-
matched to diabetic subjects (n = 141controls, and
n = 223cases) as closely as possible, with a median age of
52 years in control group and 53 years in the T2DM group.
The clinical and biochemical characteristics of age-
matched study subjects are listed in Table 3. The median
weight of age-matched T2DM group subjects (82 [range,
46–135] kg) was higher than that of age-matched con-
trol individuals. In the T2DM group, values for BMI,
SBP, DBP, WC, fasting plasma glucose, and TGs were
higher, whereas HDL levels were lower than those in the
age-matched control group. In contrast, height, total
cholesterol, and LDL levels, as well as the proportion
of male subjects were similar between the two age-
matched groups.
Table 2 Clinical and biochemical characteristics of the general study cohorts
Control subjects Type 2 diabetic patients P-value
N 928 408
Male,% (n) 27.7% (257) 44.6% (182) <10−5
Age, years 32 (18–61) 59 (29–84) <10−5
Weight, kg 63 (40–147) 80 (46–135) <10−5
Height, cm 165 (140–197) 165 (148–188) 0.154
BMI, kg/m2 23.0 (15.1–54.0) 29.3 (18.2–47.6) <10−5
Systolic blood pressure, mm Hg 110 (60–150) 130 (100–220) <10−5
Diastolic blood pressure, mm Hg 70 (50–100) 80 (60–130) <10−5
Waist circumference, cm 80 (48–180) 94 (60–160) <10−5
Hip circumference, cm - 100 (62–165) -
Waist/hip ratio - 0.95 (0.54–1.83) -
Glucose, mmol/L 4.9 (3.2–7.8) 9.6 (3.6–30.5) <10−5
Cholesterol, mmol/L 4.2 (2.0–11.8) 5.2 (2.1–16.7) <10−5
Triglycerides, mmol/L 1.0 (0.2–6.5) 1.8 (0.2–17.6) <10−5
Low-density lipoproteins, mmol/L 3.88 (1.05–15.5) 4.775 (0.23–8.67) <10−5
High-density lipoproteins, mmol/L 1.32 (0.59–2.8) 1.27 (0.6–3.6) 0.001
HbA1c, % 5.4 (4.0–7.3) 7.6 (4.4–16.4) <10−5
Insulin, μIU/mL - 12.10 (0.02–97.0) -
C-peptide, ng/mL - 4.20 (0.08–36.30) -
Data are expressed as median (range) unless otherwise specified
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Genetic analysis ofT2DM markersin the age-matched and
general T2DM and control cohorts
We genotyped 32 common SNPs (representing 25
genes/loci), of which28 were in HWE (Additional file 1).
Four polymorphisms that did not conform to HWE
criteria were excluded from subsequent analyses. In
the age-matched T2DM and control Kazakh cohorts,
logistic regression analysis after adjustments for age
and gender revealed four SNPs within four distinct
loci that were significantly associated with T2DM as
follows: rs9939609 (FTO), OR = 1.52, CI [1.03–2.26],
P = 0.04; rs13266634(SLC30A8), OR = 0.68, CI [0.49–
0.93], P = 0.02; rs7961581(TSPAN8/LGR5), OR = 1.54,
CI [1.05–2.27], P = 0.03; rs1799883(FABP2), OR = 1.51,
CI [1.06–2.13], P = 0.02) (Table 4). In addition, two
additional SNPs within the FTO gene, rs3751812 and
rs8050136, tended to be associated with T2DM (P < 0.1).
Subsequently, these associations were also tested in general
T2DM and control cohorts (Additional file 2, n = 1336)
and significant associations were found betweenT2DM
and rs1799883 (FABP2), rs3751812 (FTO), rs8050136
(FTO),and rs9939609 (FTO),with statistical power
values of 75%, 90%, 88%, and 95%, respectively.
Genetic analysis of BMI, obesity, and other metabolic
parameters in the general unmatched control cohort
Associations between BMI and SNPs that were found to
be associated with T2DM (as previously mentioned) were
tested in the general control group (Additional file 3). Data
from several individuals were excluded from analyses be-
cause of missing parameters and genotype data. Thus, for
FTO rs3751812 (P = 0.046) and FTO rs8050136 (P = 0.03),
the highest BMI values were identified in TT and AA
genotype-carriers, respectively. SBP was higher (P = 0.046)
and HDL levels were lower (P = 0.02) for FABP2
rs1799883 TT genotypes (Additional files 4 and 5) com-
pared to those parameters in non-carriers. Polymorphisms
within the FTO gene were also associated with LDL levels
(rs3751812: P = 0.04; rs8050136: P = 0.03; rs9939609:
P = 0.02) (Additional file 6) and cholesterol levels
(rs9939609: P = 0.04) (Additional file 7). However, no asso-
ciations with TG and HbA1c levels were found for any of
the six studied SNPs (data not shown).
Several studies have shown that obesity is likely to be
a major risk factor for T2DM onset. Therefore, we
tested the association between all 28 SNPs and obesity
status (Additional file 8). After adjustments for age
and gender, and considering only extreme BMI values
(i.e. < 25 and >30), only FTO polymorphisms were as-
sociated with obesity risk (rs3751812: OR = 1.51, CI
[1.14–1.99], P = 0.003, power = 72%; rs850136:
OR = 1.52, CI [1.15–2.01], P = 0.003, power = 74%;
rs9939609: OR = 1.44, CI [1.09–1.92], P = 0.01,
power = 60%).
Finally, 1336 subjects were divided into two groups ac-
cording to presence or absence of MS; 489 did not have
Table 3 Clinical and biochemical characteristics of the Kazakh study cohorts matched for age
Control subjects Type 2 diabetic subjects P-value
N 141 223
Male,% (n) 41,1% (58) 46,6% (104) 0.39
Age, years 52 (43–61) 53 (40–63) 0.11
Weight, kg 72 (47–125) 82 (46–135) <10−5
Height, cm 165 (140–192) 166 (148–188) 0.31
BMI, kg/m2 26.56 (17.2–43.1) 29.74 (18.4–47.2) <10−5
Systolic blood pressure, mm Hg 120 (90–140) 130.0 (100–220) <10−5
Diastolic blood pressure, mm Hg 80 (60–90) 80 (60–130) <10−5
Waist circumference, cm 89 (60–180) 94 (60–160) 0.01
Hip circumference, cm - 100 (63–165) -
Waist/hip ratio - 0.95 (0.54–1.83) -
Glucose, mmol/L 5.15 (3.8–6.5) 9.2 (4.1–30.5) <10−5
Cholesterol, mmol/L 4.9 (2.4–11.8) 5.2 (2.8–16.7) 0.12
Triglycerides, mmol/L 1.2 (0.4–3.8) 1.9 (0.2–17.6) <10−5
Low-density lipoproteins, mmol/L 4.57 (1.78–15.50) 4.71 (1.56–8.67) 0.47
High-density lipoproteins, mmol/L 1.32 (0.7–2.8) 1.23 (0.62–3.6) 0.009
HbA1c, % 5.9 (4.5–6.7) 7.65 (4.4–16.4) <10−5
Insulin, μIU/mL - 12.70 (0.02–97.0) -
C-peptide, ng/mL - 4.20 (0.14–12.0) -
Data are expressed as median (range) unless otherwise specified
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T2DM and MS (control group) and 208 had at least
three components of the MS (patients). The risk of de-
veloping at least three components of MS was associated
with FTO polymorphisms (rs3751812: OR = 1.49, CI
[1.04–2.14], P = 0.03, power = 61%; rs8050136: OR = 1.52,
CI [1.06–2.19], P = 0.02, power = 65%; rs9939609:
OR = 1.59, CI [1.10–2.32], P = 0.01, power = 72%) and
FABP2 polymorphism (rs1799883: OR = 1.65, CI [1.16–
2.38], P = 0.006, power = 82%; Additional file 9).
Comparison of allele frequencies in Kazakh population
with population data from the HapMap database
We also comparatively analysed the differences in allele
frequencies between the Kazakh population and popu-
lations of different ethnic origins (listed as follows)
represented in the HapMap database: Africans (Yoruba in
Ibadan, Nigeria; Luhya in Webuye, Kenya); Americans of
African ancestry (South West USA); Maasai (Kinayawa,
Kenya), Americans (Mexicans in Los Angeles, USA),
Asians (Gujarati Indian from Houston, USA, Han Chinese
in Beijing, China; Chinese population in Metropolitan
Denver, USA; Japanese in Tokyo, Japan), and Europeans
(Utah residents with Northern and Western European an-
cestry, USA; Toscani, Italy; Table 5).
As expected, significant differences in allele frequencies
were found between Kazakhs and representatives of other
ethnic groups for a large number of SNPs (Table 5). For
the African American population, genotype data for only
25 of 28 studied SNPs were available. Allele frequencies of
22 of these 25 SNPs were significantly different from those
Table 4 Association of candidate SNP loci with type 2 diabetes in the age-matched Kazakh study cohorts
SNP Gene Major/ Minor allele Minor allele frequency Odds ratio
(95% CI)
P-value
Control (n = 141) T2DM (n = 223)
rs3751812 FTO G/T 0.24 0.29 1.41 (0.97–2.07) 0.07
rs8050136 FTO C/A 0.25 0.3 1.37 (0.94–2.01) 0.09
rs9939609 FTO T/A 0.23 0.29 1.52 (1.03–2.26) 0.04
rs10811661 CDKN2A/B T/C 0.23 0.24 1.03 (0.71–1.50) 0.86
rs2383208 CDKN2A/B A/G 0.22 0.22 0.99 (0.67–1.48) 0.96
rs1111875 HHEX T/C 0.38 0.42 1.19 (0.87–1.64) 0.26
rs13266634 SLC30A8 C/T 0.4 0.32 0.68 (0.49–0.93) 0.02
rs4506565 TCF7L2 A/T 0.16 0.19 1.22 (0.82–1.84) 0.34
rs5215 KCNJ11 T/C 0.33 0.36 1.15 (0.83–1.59) 0.4
rs7756992 CDKAL1 A/G 0.31 0.33 1.11 (0.79–1.56) 0.55
rs4712523 CDKAL1 A/G 0.3 0.34 1.18 (0.85–1.65) 0.31
rs9465871 CDKAL1 T/C 0.29 0.31 1.07 (0.76–1.51) 0.67
rs7961581 near TSPAN8/LGR5 T/C 0.21 0.29 1.54 (1.05–2.27) 0.03
rs864745 JAZF1 T/C 0.38 0.39 1.04 (0.77–1.43) 0.76
rs12779790 near CDC123/CAMK1D A/G 0.18 0.16 0.89 (0.55–1.44) 0.64
rs10490072 BCL11A T/C 0.12 0.12 0.96 (0.57–1.61) 0.88
rs10923931 NOTCH2 G/T 0.05 0.07 1.56 (0.77–3.34) 0.22
rs7578597 THADA T/C 0.06 0.05 0.91 (0.46–1.80) 0.78
rs2025804 LEPR A/G 0.67 0.6 0.76 (0.55–1.06) 0.12
rs2641348 ADAM30 A/G 0.04 0.07 1.85 (0.90–4.14) 0.11
rs9472138 near VEGFA C/T 0.19 0.2 1.05 (0.71–1.58) 0.79
rs1042714 ADRB2 C/G 0.31 0.3 0.97 (0.68–1.37) 0.87
rs4994 ADRB3 A/G 0.16 0.19 1.16 (0.76–1.78) 0.48
rs1799883 FABP2 C/T 0.3 0.39 1.51 (1.06–2.13) 0.02
rs1801282 PPARG C/G 0.11 0.13 1.23 (0.78–2.00) 0.37
rs8192678 PPARGC1A C/T 0.36 0.32 0.82 (0.59–1.15) 0.26
rs780094 GCKR C/T 0.4 0.38 0.9 (0.58–1.39) 0.63
rs7944584 MADD A/T 0.11 0.15 1.46 (0.77–2.98) 0.26
All SNPs are analyzed in additive model. Logistic regression models were used adjusted for age and sex. Bold and italic P-values are statistically significant with P < 0.05
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of the Kazakh population. For Caucasians, genotype
data were available for 27 SNPs. Allele frequencies of
17 SNPs were significantly different between Caucasians
and Kazakhs. For Asian populations, genotype data were
also available for 27 of the 28 studied SNPs. Allele
frequencies of 18 of these 27 SNPs were significantly dif-
ferent compared to those of the Kazakh population.
Discussion
In the present study, we addressed whether genetic variants
previously reported [8, 12, 23–43] to be associated with sus-
ceptibility to T2DM, obesity, and MS in other ethnic groups
are also associated with obesity-related phenotypes and/or
diseases in a Kazakh cohort. Kazakhs are Turkic-speaking
people that live in several Central Asian countries including
Kazakhstan, Uzbekistan, Kyrgyzstan, as well as in Russia,
Mongolia, and China. From a historic point of view, and
because of scarce genetic data, it has been suggested that
the Kazakh population was formed as a result of admixture
of European and Asian populations [23, 24].
To our knowledge, this is the first study showing sig-
nificant associations between genetic polymorphisms
within SLC30A8, TSPAN8/LGR5, FABP2, and FTO genes
and susceptibility to T2DM in age-matched groups in-
cluding Kazakh subjects. We also found that SNPs in
FTO and FABP2 are significantly associated with suscep-
tibility to MS. Finally, SNPs in FTO were found to be
significantly associated with BMI and susceptibility to
obesity in the general unmatched control group.
The rs13266634 T allele in SLC30A8 was shown to have
a protective effectagainstT2DM in a Kazakh age- and sex-
matched cohort (OR = 0.68). These results are in agree-
ment with those of several large-scale studies suggesting
the involvement of SLC30A8 in the development of
T2DM [7, 44, 45]. It has thus been hypothesized that the
SLC30A8 gene product regulates zinc ion concentration in
β-cells, as zinc has an important role in the regulation of
maturation, storage, and secretion of insulin by these cells
[46]. Comparative analysis of rs13266634 allelic frequen-
cies showed significant differences between the Kazakh
population and most other population groups from the
HapMap database, except for Asian populations. We also
observed a significant association between TSPAN8/LGR5
rs7961581 and T2DM (OR = 1.54) in our age-matched co-
hort. This was in accordance with the study by Zhou et al.
[47] who reported a similar association in Japanese and
Chinese populations [47]. Interestingly, rs7961581 allele
frequencies in the Kazakh population were not different
from those in the Japanese and Chinese populations. How-
ever, in the present study, these associations were not found
in the general unmatched T2DM and control cohorts.
The FABP2 gene encodes a small-bowel fatty acid-
linked form of the protein, which belongs to a family of
proteins that regulates lipid transport and metabolism
[46]. FABP2 rs1799883 was significantly associated with
T2DM in the age-matched Kazakh cohort (OR = 1.51)
and these findings were also confirmed in the general
unmatched cohort (OR = 1.41) with a statistical power
of 75% (Additional file 2). This is in agreement with pre-
vious studies showing an association between FABP2
gene polymorphisms and insulin resistance and T2DM,
as well as a meta-analysis that indicated a significant
association between the rs1799883 polymorphism and
susceptibility to T2DM among Asian, but not Caucasian,
populations [8]. In addition, we showed that rs1799883
is significantly associated with MS (OR = 1.65), with a
statistical power of 82%, as well as with decreased HDL
concentrations and increased SBP in control subjects;
this might be important for the development of T2DM.
This was also in agreement with previously reported as-
sociations between FABP2 genetic polymorphism and
dyslipidaemia (high plasma concentration of TGs and
low concentration of HDL) and MS in elderly subjects
[47–50]. In addition, comparative analysis showed that
for rs1799883 there are significant differences in allele
frequencies between Kazakh and African, Asian, and
Caucasian populations.
In the present study, polymorphisms in the FTO gene
(rs3751812, rs8050136, andrs9939609) were found to be
significantly associated with BMI, obesity, MS, LDL, and
cholesterol levels in the general control Kazakh cohort.
These results are consistent with those of previous studies
suggesting the involvement of this gene in lipid metabo-
lism [51, 52], obesity, T2DM [51–54], and MS in different
populations [55–57]. Our sample size (n = 838) had power
values of 72%, 74%, and 60% to detect associations
between obesity status and rs3751812 (OR = 1.51),
rs8050136 (OR = 1.52), and rs9939609 (OR = 1.44),
respectively. Furthermore, sample size (n = 697)
allowed for the detection of associations between
rs3751812 (OR = 1.49), rs8050136 (OR = 1.52), and
rs9939609 (OR = 1.59) and MS with power values of
61%, 65%, and 72%, respectively.
FTO polymorphisms were also significantly associated
with T2DM in the age-matched T2DM and control co-
horts (Table 4), as well as in the general T2DM and con-
trol cohorts (power > 90%; Additional file 2). It has been
suggested for many years that FTO might play an impor-
tant role in controlling energy expenditure and might also
be involved in energy homeostasis. However, the exact
function of the FTO gene and the molecular mechanisms
linking these non-coding variants with obesity remain un-
known. Interestingly, although the IRX3 gene is located
half a million base pairs away from the FTO gene locus, it
has been recently shown that regions of the FTO gene that
are associated with obesity physically interact with an
IRX3 gene promoter; therefore, it is possible that the IRX3
gene is also linked to obesity [58].
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In the present study, genetic polymorphisms in
CDKN2A/B, HHEX, TCF7L2, KCNJ11, CDKAL1, JAZF1,
CDC123/CAMK1D, BCL11A, NOTCH2, THADA, LEPR,
ADAM30, VEGFA, ADRB2, ADRB3, PPARG, PPARGC1A,
GCKR, andMADD genes were not significantly associated
with T2DM risk, MS, obesity, or with quantitative me-
tabolic traits (TGs, cholesterol, LDL, HDL), blood pres-
sure, or BMI. Although many studies have demonstrated
significant associations between variants of these genes
and some T2DM and/or obesity-related phenotypes
[8, 12, 26, 27, 29, 33, 34, 35–38],other reports have
failed to identify such associations [42, 59]. Negative
findings in our Kazakh cohort might be potentially ex-
plained by different allele frequencies in different ethnic
groups and/or the fact that the same polymorphism might
have a different impact on disease susceptibility in diffe-
rent populations consisting of different ethnicities, and/or
insufficient power of the present study to detect such
differences.
Conclusion
In conclusion, we confirmed previously demonstrated as-
sociations between polymorphisms in SLC30A8, TSPAN8/
LGR5, FABP2, and FTO and T2DM in a Kazakh cohort.
Interestingly, polymorphisms in FTO were significantly
associated with susceptibility to MS and obesity, higher
BMI, lower HDL concentrations, and higher SBP in our
control group. To our knowledge, this is the first asso-
ciation study assessing how gene variants affect predis-
position to metabolic diseases in a Kazakh cohort. The
positive results as well as negative findings of the
present study should be confirmed in larger cohorts of
Kazakh subjects.
Some limitations of this study should be acknow-
ledged. The case-control design is subject to selection
biases and only allows for the examination of asso-
ciations between genetic polymorphisms and various
phenotypes, whereas causative effect cannot be demon-
strated. In addition, only a limited number of SNPs (28)
could be analysed in our cohort and only subsets of the
entire T2DM and control cohorts could be matched for
age and gender. Results with statistical power of less
than 80% should therefore be taken with caution [10,
20]. Thus, a larger sample size, in particular for age-
matched patients and controls, would be required to as-
sess whether the lack of association demonstrated in the
present study is due to real biological differences attri-
buted to a particular ethnic background or due to lack
of statistical power. Another possible limitation of our
study might be the fact that no Bonferroni correction
was applied to avoid type 1 error due to multiple compari-
sons. If Bonferroni’s correction was applied to P-values
obtained in our study, the thresholds of significance for
each comparison would be 0.0018 for 28 comparisons.
After the correction, only the rs9939609 polymorphism
would be associated with type 2 diabetes in our Kazakh
cohort. However, although there is the chance of type 1
error due to multiple comparisons, we believe that this
correction might be too conservative as the chosen poly-
morphisms have already been associated with metabolic
features in many studies, and because they were tested for
replication in the present study.
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